Sorafenib and Midostaurin drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Sorafenib (sorafenib) and Midostaurin (midostaurin). Common drug interactions include febrile neutropenia among females and pancytopenia among males.

The phase IV clinical study analyzes what interactions people have when they take Sorafenib and Midostaurin. It is created by eHealthMe based on reports of 40 people who take the same drugs from the FDA, and is updated regularly.

What is Sorafenib?

Sorafenib has active ingredients of sorafenib. eHealthMe is studying from 3,201 Sorafenib users. Check the latest studies of Sorafenib.

What is Midostaurin?

Midostaurin has active ingredients of midostaurin. eHealthMe is studying from 1,137 Midostaurin users. Check the latest studies of Midostaurin.



On Jul, 13, 2026

40 people who take Sorafenib and Midostaurin together, and have interactions are studied.

Sorafenib and Midostaurin drug interactions.

What are the common drug interactions of Sorafenib and Midostaurin, by gender? *:

female:

  1. Febrile neutropenia (fever with reduced white blood cells)
  2. Thrombocytopenia (decrease of platelets in blood)
  3. Anaemia (lack of blood)
  4. Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
  5. Bacteraemia (presence of bacteria in the blood)
  6. Colitis (inflammation of colon)
  7. Drug ineffective
  8. Empyema (collection of pus in a cavity in the body)
  9. Hyperbilirubinaemia (excess of bilirubin in the blood)
  10. Hypoglycaemia (deficiency of glucose in the bloodstream)

male:

  1. Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
  2. Acute myeloid leukaemia recurrent (acute cancer in which the bone marrow makes abnormal myeloblast- recurrent)
  3. Device related infection
  4. Diarrhoea
  5. Drug ineffective
  6. Headache (pain in head)
  7. Neutropenia (an abnormally low number of neutrophils)
  8. Pyrexia (fever)
  9. Rash maculo-papular (red area on the skin that is covered with small confluent bumps)
  10. Urinary tract infection

What are the common drug interactions of Sorafenib and Midostaurin, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

  1. Acute myeloid leukaemia recurrent (acute cancer in which the bone marrow makes abnormal myeloblast- recurrent)
  2. Bone marrow failure
  3. Drug intolerance (drug sensitivity)
  4. Lymphadenopathy (disease or enlargement of lymph nodes)
  5. Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
  6. Skin toxicity (skin damage due to toxin/poison)
  7. Myelosuppression (a decrease in the production of blood cells)

10-19:

  1. Alanine aminotransferase increased
  2. Bacteraemia (presence of bacteria in the blood)
  3. Drug ineffective
  4. Febrile neutropenia (fever with reduced white blood cells)
  5. Acidosis (build-up of carbon dioxide in the blood)
  6. Haemorrhage intracranial (bleeding within the skull)
  7. Pneumonia fungal
  8. Anaemia (lack of blood)
  9. Thrombocytopenia (decrease of platelets in blood)
  10. Blood creatinine increased

20-29:

  1. Anaemia (lack of blood)
  2. Drug ineffective
  3. Febrile neutropenia (fever with reduced white blood cells)
  4. Thrombocytopenia (decrease of platelets in blood)
  5. Death
  6. Leukaemia recurrent (repeat cancer of bone marrow or blood cells)

30-39:

  1. Erythema nodosum (skin inflammation that results in reddish, painful, tender lumps most commonly located in the front of the legs below)
  2. Septal panniculitis (a condition of the subcutaneous fat affecting the layer of adipose tissue that lies between the dermis and underlying fascia)
  3. Acute myeloid leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts)
  4. Drug ineffective

40-49:

  1. Neutropenia (an abnormally low number of neutrophils)
  2. Thrombocytopenia (decrease of platelets in blood)
  3. Anaemia (lack of blood)
  4. Device related infection
  5. Diarrhoea
  6. Febrile neutropenia (fever with reduced white blood cells)
  7. Graft versus host disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body)
  8. Headache (pain in head)
  9. Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
  10. Pyrexia (fever)

50-59:

  1. Acute myocardial infarction (acute heart attack)
  2. Asthenia (weakness)
  3. Bacteraemia (presence of bacteria in the blood)
  4. Duodenal ulcer
  5. Endocarditis (inflammation in heart muscle)
  6. Epistaxis (bleed from the nose)
  7. Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
  8. Hyporesponsive to stimuli (abnormally low degree of responsiveness on an agent, action, or condition)
  9. Hypotension (abnormally low blood pressure)
  10. Pneumonia respiratory syncytial viral (respiratory syncytial virus (rsv) is a very common virus that leads to mild, cold-like symptoms in adults and older healthy children)

60+:

  1. Febrile neutropenia (fever with reduced white blood cells)
  2. Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
  3. Vaginal haemorrhage (vaginal bleeding)
  4. Bacteraemia (presence of bacteria in the blood)
  5. Leukaemia recurrent (repeat cancer of bone marrow or blood cells)
  6. Oliguria (not enough urine)
  7. Staphylococcal infection (an infection with staphylococcus bacteria)
  8. Colitis (inflammation of colon)
  9. Empyema (collection of pus in a cavity in the body)
  10. Hyperbilirubinaemia (excess of bilirubin in the blood)

What are the existing conditions these people have? *

  1. Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 36 people, 90.00%
  2. Bone Marrow Conditioning Regimen: 2 people, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Sorafenib and Midostaurin?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Sorafenib and Midostaurin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Sorafenib:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Midostaurin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Sorafenib and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Midostaurin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on sorafenib and midostaurin (the active ingredients of Sorafenib and Midostaurin, respectively), and Sorafenib and Midostaurin (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: